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Sary Hepatic parenchymal vasoconstriction increases cytotoxic drug uptake into hepatic metastases by
increasing the tumour to liver blood flow ratio. Prolonged infusion of the vasoconstrictor vasopressin does not
result in sustained vasoconstriction, and this may limit the benefit of vasopressin in infusional chemotherapy.
We have assessed whether loss of vasopressin-induced vasoconstriction is mediated by nitric oxide. Hepatic
and tumour blood flow were continuously monitored, in an animal hepatic tumour model, by laser Doppler
flowmetry. The response to regionally infused vasopressin and the nitric oxide inhibitor N-nitro-L-arginine
methyl ester (L-NAME) were assessed over a 30 min infusion period. The vasopressin-induced vasoconstrictor
effect diminished after 15min despite continued infusion. Vasoconstriction was significantly prolonged when
L-NAME was infused in addition to vasopressin. The increase in tumour to normal blood flow ratio was
greater over the infusion period when L-NAME was co-administered with vasopressin. Our results suggest that
the loss of vasopressin-induced vasoconstriction seen in liver parenchyma after regional infusion is prevented
by the nitric oxide synthase inhibitor L-name and may be mediated by nitric oxide.
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Hepatic artenral fluorodeoxyuridine (FUDR) infusion has
been shown to confer a survival benefit (Rougier et al., 1992;
Allen-Mersh et al., 1994) and a higher partial response than
with systemic chemotherapy (Dworkin and Allen-Mersh,
1991) in the treatment of colorectal liver metastases. As a
result, more patients with colorectal liver metastases will be
offered regional infusional treatment.
Regionally infused vasoactive agents aim to increase the
proportion of hepatic arterial blood flow to tumour as com-
pared with normal liver and may be of benefit in enhancing
the efficacy of regional infusion chemotherapy. We have
previously shown a relationship between tumour blood flow
and uptake of 5-fluorouracil (5-FU) (Dworkin et al., 1993).
Previous radiological studies using the parenchymal
vasoconstrictor vasopressin to enhance tumour blush during
angiography have suggested that the duration of effect of
regional vasopressin on the hepatic arterial circulation is
short (Conn et al., 1973). Using regional angiotensin II,
Sasaki et al. (1985) demonstrated a 3-fold increase in tumour
blood flow, which was maximal within 1-2 min and
decreased rapidly thereafter. We have shown (Dworkin et al.,
1992) that after initial vasopressin-induced vasoconstriction
there is a loss of effect despite continued infusion of the
vasoactive agent.
Following the identification of nitric oxide (NO) as an
important vasodilator substance produced by endothelial
cells (Moncada et al., 1991), it has been shown that NO is
the mediator of ATP-induced vasodilation in the hepatic
arterial bed (Mathie et al., 1991) and may be involved with
endothelin I in the regulation of basal sinusoidal tone within
the liver (Kawada et al., 1993). We have tested the hypothesis
that the loss of vasoconstrictor effect seen in response to
prolonged vasopressin infusion is due to local NO release. In
order to do this, we have measured hepatic and tumour
blood flow changes in response to regional vasopressin
infusion with and without the addition of the specific nitric
oxide inhibitor N-nitro-L-arginine methyl ester (L-NAME).
cells of the HSN tumour line, which produced 1-4 tumours
of less than 8 mm diameter on the surface of the liver.
Laparotomy was performed under halothane anaesthesia, the
gastroduodenal artery exposed in the lesser omentum and
cannulated with polyethylene tubing (0.28 i.d. x
0.61 mm o.d.; Portex) with the aid of an operating micro-
scope.
Perfusion measurements
Perfusion measurements were carried out using laser Doppler
flowmetry (MBF3D; Moor Instruments), in which incident
laser light (wavelength 780-820 nm) is scattered in the tissue
and undergoes a frequency shift in proportion to red cell
speed and concentration, and which has an estimated
measuring depth of 1-2 mm. Laser Doppler output is
recorded on an arbitrary scale in flux units which are propor-
tional to tissue perfusion. A 30 x 1 mm surface probe was
carefully applied to the surface of the liver using a probe
holder to minimise movement between the probe tip and the
liver surface. A second probe was similarly placed in contact
with the tumour surface such that the measurements were
from tumour tissue and not influenced by adjacent liver.
Movement artefact was minimised by careful positioning of
the probes using the lowest display time constant and a
recording rate of 20 Hz. Subsequent readings were performed
with a time constant of 3.0 s at 0.25 Hz and were measured
for 10 min before and for 30 min during the infusion
period.
Bloodpressure monitoring
Blood pressure was monitored by means of an 18g Teflon
cannula (Critikon) inserted into the right carotid artery and
blood pressure measured continuously using a pressure trans-
ducer (FCO 11; Furness, UK) coupled to a PC data-logging
system.
Methods
Experiments were performed in male CBH/cbi rats (300-
350 g) 21-25 days after intraportal injection of 106 tumour
Correspondence: TG Alen-Mersh
Received 20 September 1994; revised 9 December 1994; accepted 4
January 1995
Regional infusions
Vasopressin (Sigma) and L-NAME (Sigma) were prepared at
the start of each experiment by dissolving in 0.9% sodium
chloride. Infusions were carried out directly via the gastro-
duodenal artery into the hepatic arterial circulation using an
infusion pump (Harvard) at a rate of 50 minm-1.There were four experimental groups involving one of the
following four infusion schedules:
1. 0.9% saline infusion (30 min);
2. vasopressin infusion (0.5tg min-I for 30 min);
3. L-NAME (0.5mgmin-' for 30min);
4. Vasopressin (0.5iLgmin'I for 30min) and L-NAME
(0.5 mg mini ' for 30 min or 0.7 mg min ' for 5 min at
the onset of recovery from vasoconstriction, which was
apparent from a sustained trend of increasing flow over
a 5 min period).
The extent and duration of vasoconstriction were assessed
by measuring the average percentage laser Doppler flux fall
from baseline values seen during and at the end ofthe 30 min
infusion. Average changes were also calculated for the first
and second half of the infusion periods. Tumour to normal
ratios were calculated by dividing tumour flux by liver flux.
Differences between groups were compared using an un-
paired Student t-test and within a group using a paired
t-test.
Results
Twenty-eight animals were studied and the percentage flux
change at 30 min is shown in Figure 1 for each group.
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Fue 1 Percentage flux change at the end of a 30 min infusion.
Mean and standard deviations are marked. There was a
significant reduction in both tumour and liver parenchymal flux
with vasopressin and vasopressin + L-NAME. The drop in flux
was significantly greater with vasopressin and L-NAME com-
pared with vasopressin alone.
Liverparenchymalperfusion
Vasopressin caused a marked vasoconstriction during the
early infusion period, although within 15 min this returned
towards baseline values. Figure 2 shows typical flux changes
in a single study in the vasopressin infusion group. Overall,
in the vasopressin only group, the flux fall from baseline seen
in the first 15 min (mean 45.0%, s.d. 12.0%) was significantly
(P<0.0001) greater than that seen in the second 15 min
(mean 11.0%, s.d. 12.0%) owing to recovery from vasocon-
striction (tachyphylaxis effect).
When L-NAME was co-administered with vasopression,
the vasoconstrictor effect was prolonged and there was no
significant (P = 0.06) difference in the flux fall from baseline
for the first 15 min of the infusion (mean 63.1%, s.d. 15.4%)
compared with the second (mean 54.0%, s.d. 24.6%), reflect-
ing a more prolonged vasoconstrictor effect than that seen
with vasopressin alone. At 30 min the flux fall was
significantly greater (P<0.002) for the combined
vasopression/L-NAME group (mean 54.0%, s.d. 25.8%) than
for any other group (Figure 1).
If an infusion of L-NAME was added at the time when
vasopressin-induced vasoconstriction was diminishing and
perfusion starting to return to baseline levels (n = 3 animals),
then the full vasoconstrictor response to vasopressin was
restored in all cases (Figure 3).
L-NAME administered alone caused a small but significant
(P<0.001) fall in perfusion (mean flux fall 9.0%, s.d. 5.6%)
which was maintained over the infusion compared with the
saline group (mean flux increase 4.6%, s.d. 5.7%).
Twnourperfusion
There was a significant fall in tumour perfusion at 30 min
which was significantly (P<0.05) greater for both vasopres-
sin (mean 20.4%, s.d. 20.0%) and the combined vasopressin/
L-NAME group (mean 36.0%, s.d. 26.7%) compared with
saline (mean flux increase 3.5%, s.d. 13.7%) at the end of the
infusion period (Figure 1). There was no significant difference
(P = 0.15) between the vasopressin group and the combined
vasopressin/L-NAME group.
The vasopressin-induced tumour perfusion fall was signifi-
cantly (P<0.005) greater during the first half of the infusion
period (mean 37.3%, s.d. 16.5%) than during the second half
(mean, 23.5%, s.d. 17.4%). This was in contrast to the group
receiving combined vasopressin/L-NAME, in which there was
no significant (P = 0.25) difference in the perfusion fall in the
first halfof the infusion (mean, 46.7%, s.d. 14.6%) compared
with the second (mean 40.3%, s.d. 24.2%).
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Fugwe 2 Typical laser Doppler trace showing perfusion change
in response to a 30 min vasopressin infusion. Blood pressure
(mmHg) is shown on the uppermost trace, liver and tumour flux
(mV) are on the middle trace and the tumour to normal flux ratio
on the lower trace. After an initial baseline period (Omin), a
30 min infision of vasopressin was commenced. After 15 min
from the onset of vasopressin infusion, the extent of vasopressin-
induced vasoconstriction diminished.
There was a significant (P<0.05) flux fall over the infusion
period in the L-NAME only group (mean 17.5, s.d. 20.3)
compared with the saline control group (mean rise 0.9%, s.d.
10.2%), but this was not significantly different by 30min
from the onset of L-NAME infusion (Figure 1).
Twnour to normalflux ratio (TNR)
The average tumour to normal flux ratios over the entire
infusion period were not significantly (P = 0.2) changed for
the vasopressin group (mean increase 10.5%, s.d. 34.7%)
compared with saline (mean fall 1.7%, s.d. 12.4%). However,
this masked a rise in TNR for the first half of the infusion
(mean increase 30.0%, s.d. 37.0%) which was significantly
(P<0.0002) greater than the second half in which the TNR
fell (mean fall 11.4%, s.d. 27.3%).
Combined vasopressin/L-NAME did produce a significant
rise (P<0.02) in the average TNR for the infusion period
(mean 67.6%, s.d. 62.5%) compared with saline (mean fall
1.7%, s.d. 12.4%). There was no significant (P = 0.10) differ-
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Fugwe 3 Laser Doppler trace from a single study, showing
modification of the vasopressin response after addition of L-
NAME at the time point when the vasopressin-induced vasocon-
strictor effect diminished. This reversed the vasopressin tachy-
phylaxis effect and restored the vasoconstriction.
ence in the rise seen in the first half (mean 85.6%, s.d.
87.8%) of the infusion compared with the second half (mean
49.6%, s.d. 40.0%).
DisoB
Pressor agents such as vasopressin, angiotensin and adren-
aline increase the tumour to liver parenchymal flow ratios for
the delivery of microspheres and other tracer isotopes admin-
istered directly into the hepatic artery (Burton et al., 1985;
Ackermann et al., 1988; Goldberg et al., 1991; Hemmingway
et al., 1991). This may be due to differences in the smooth
muscle content of the arteriolar vessels of normal liver and
tumour, resulting in a selective arterial vasoconstriction
(Krylova, 1969). Previous studies of the effects of vasoactive
agents have used a short infusion or bolus doses of vaso-
active agent. While this may be of benefit in enhancing the
delivery of bolus chemotherapy or labelled microspheres, it
cannot be assumed that the effect is sustained during pro-
longed vasoactive infusion as would be required with infus-
ional chemotherapy. Previous studies have suggested that the
potential benefit of vasoactive manipulation may only last a
few minutes (Sasaki et al., 1985). This study confirms the
limited duration of the maximal vasoconstrictor effect of
continued regional vasopressin infusion into the hepatic
arterial circulation. It also shows that the tachyphylaxis effect
which is seen approximately 15 min after commencement of
vasopresin infusion is not seen throughout the 30 min study
period when L-NAME is co-adminiser with vasopressin.
This vasopressin tachyphylaxis effect might therefore be due
to nitric oxide release within liver parenchymal vessels. Fur-
ther studies in a more suitable long-term model would be
necessary to determine whether the effect is sustained over a
period of hours or days.
Vasopressin also produced a vasoconstriction within the
tumour circulation, suggesting that the view of the tumour
circulation as being unresponsive to pressor agents may not
be correct. This response may have been produced by paren-
chymal vessels supplying the tumour or by tumour vessels.
Tachyphylaxis to this effect was not apparent as in the liver
parenchyma and, consequently, while the addition of L-
NAME prolonged the effect of the first half of the infusion,
there was no sigificant difference at the end of the infusion
compared with vasopressin alone. This suggests that this
vasoconstrictor effect arose from tumour vessels in which the
role of nitric oxide in the regulation of vessel tone may not
be the same as in normal vessels.
Despite the reduction in tumour flow with vasopressin
there was an increase in tumour to normal flow ratio,
offering the potential for therapeutic advantage by increasing
the dose of the cytotoxic drug delivered. This effect was
sustained by prolonging the effect of vasopressin infusion
using L-NAME. Studies assessing the extent of the effect of
combined vasopressin and L-NAME on tumour cytotoxic
drug uptake in liver metastases would be justified.
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